Milestone Pharmaceuticals (MIST) Earnings Date, Estimates & Call Transcripts $1.70 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Milestone Pharmaceuticals Earnings Summary Milestone Pharmaceuticals released Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.20, which missed the consensus estimate of -$0.18 by $0.02. With a trailing EPS of -$0.84, Milestone Pharmaceuticals' earnings are expected to decrease next year, from ($0.62) to ($1.00) per share. Latest Q2 Earnings DateAug. 12EstimatedConsensus EPS (Aug. 12) -$0.18 Actual EPS (Aug. 12) -$0.20 Missed By -$0.02 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press ReleasePowered by Get Milestone Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataMIST Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MIST Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Milestone Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.11-$0.11-$0.11Q2 20251-$0.11-$0.11-$0.11Q3 20251-$0.14-$0.14-$0.14Q4 20251-$0.21-$0.21-$0.21 FY 2025 5 -$0.57 -$0.57 -$0.57 Q1 20262-$0.23-$0.23-$0.23Q2 20262-$0.20-$0.20-$0.20Q3 20261-$0.22-$0.22-$0.22Q4 20261-$0.20-$0.20-$0.20 Milestone Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025-$0.18-$0.20 -$0.02-$0.20--5/14/2025Q1 2025-$0.19-$0.31 -$0.12-$0.31--11/12/2024--$0.18-$0.14+$0.04-$0.14--8/8/2024--$0.19-$0.14+$0.05-$0.14--5/13/2024Q1 2024 -$0.26-$0.21+$0.05-$0.21--3/21/2024Q4 2023 -$0.30-$0.32 -$0.02-$0.32--11/13/2023Q3 2023 -$0.38-$0.35+$0.03-$0.35-- Milestone Pharmaceuticals Earnings - Frequently Asked Questions When did Milestone Pharmaceuticals announce their last quarterly earnings? Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on MIST's earnings history. Did Milestone Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Milestone Pharmaceuticals (NASDAQ:MIST) missed the analysts' consensus estimate of ($0.18) by $0.02 with a reported earnings per share (EPS) of ($0.20). Learn more on analysts' earnings estimate vs. MIST's actual earnings. How much revenue does Milestone Pharmaceuticals generate each year? Milestone Pharmaceuticals (NASDAQ:MIST) has a recorded annual revenue of $1 million. How much profit does Milestone Pharmaceuticals generate each year? Milestone Pharmaceuticals (NASDAQ:MIST) has a recorded net income of -$41.52 million. MIST has generated -$0.84 earnings per share over the last four quarters. What is Milestone Pharmaceuticals' EPS forecast for next year? Milestone Pharmaceuticals' earnings are expected to decrease from ($0.62) per share to ($1.00) per share in the next year. More Earnings Resources from MarketBeat Related Companies Abeona Therapeutics Earnings Date Olema Pharmaceuticals Earnings Date Aldeyra Therapeutics Earnings Date Amarin Earnings Date Benitec Biopharma Earnings Date Rocket Pharmaceuticals Earnings Date Inhibrx Biosciences Earnings Date Neurogene Earnings Date Candel Therapeutics Earnings Date Larimar Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Green Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move Higher This page (NASDAQ:MIST) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access